InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,728.80
(
0.41%
)
US TECH 100
19,528.00
(
0.90%
)
Dow Jones
42,052.19
(
0.69%
)
Brent Oil
72.91
(
0.00%
)
Bitcoin
68,353.09
(
-1.38%
)
Post# of 253510
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120661
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 252625

Thursday, 07/25/2024 12:30:22 PM

Thursday, July 25, 2024 12:30:22 PM

Post# of 253510
Re: IRA drug-price “negotiations”

Echoing what JNJ said last week about Stelara and Xarelto (#msg-174768280), AZN said on today’s 2Q24 CC that the IRA price-setting for Farziga starting in 2026 will have “very limited impact.” Exactly what this phrase means is open to interpretation, but the salient point is that IRA price-setting is apparently not going to be as deleterious to drug/biotech companies as some investors feared.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up